Merck KGaA (MRK.DE) Stock Analysis & Winston Score
Merck KGaA is a German science and technology company that makes products in three main areas: prescription drugs, life science tools, and specialty chemicals. Its healthcare division sells cancer and fertility treatments, while its life science arm supplies lab equipment and materials to researchers and pharmaceutical manufacturers worldwide. The company is one of the oldest science companies in the world, tracing its roots back to 1668 in Darmstadt, Germany. Merck KGaA earns revenue through product sales across all three divisions, with life sciences being the largest contributor. It operates globally, with significant sales in North America, Europe, and Asia, and generates roughly €22 billion in annual revenue. Its competitive edge comes from its diversified business model and deep relationships with drug manufacturers who rely on its materials to make medicines. The key growth driver is demand for biotech manufacturing tools, but a major risk is pricing pressure in its healthcare segment as competition from generic drug makers intensifies.
Winston Score: 52/100 — Average
Mixed quality — meaningful strengths and weaknesses.
- Quality: Good (19/30)
- Growth: Mixed (5/20)
- Cash Flow: Exceptional (9/10)
- Stability: Strong (8/10)
- Valuation: Strong (7/10)
- Ownership: Weak (1/15)
Key Facts
Price: €137.95
Market Cap: €59.9B
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: Frankfurt Stock Exchange


